Biological Effects and Clinical Application of the Anti-Immunoglobulin E Antibody.

Abstract

Background: Immunoglobulin E (IgE) plays a pivotal role in the pathogenesis of allergic diseases by engaging with FcεRI and FcεRII receptors, triggering allergic responses. The development of anti-IgE antibodies, such as omalizumab, has introduced a targeted approach to allergy treatment by neutralizing free IgE and dampening the allergic cascade.

Summary: This review synthesizes the current understanding of IgE's role in allergic diseases and evaluates the clinical utility of omalizumab. It specifically examines the biological mechanisms underpinning anti-IgE antibodies and their efficacy in treating moderate to severe asthma and chronic spontaneous urticaria (CSU). The paper also explores the potential of omalizumab in managing other allergic conditions and considers the long-term implications of anti-IgE therapy.

Key messages: By summarizing and elucidating the biological mechanisms and clinical applications of anti-IgE antibodies through a review of global literature from the past 5 years, this article aims to establish a theoretical foundation for developing innovative anti-allergic treatment strategies. Omalizumab has demonstrated efficacy in reducing IgE-mediated responses, offering improved clinical outcomes for patients with asthma and CSU, with promising potential in an array of allergic diseases. The long-term safety profile of anti-IgE medications remains an area of active investigation, underscoring the need for ongoing research to refine these therapies and expand their application in allergy management.